2nd Stratified Medicine Conference
22 Jan 2013 - 23 Jan 2013 - Boston, MA, USA
Stratified medicine has the potential to revolutionize medical care by utilizing an improved understanding of genetics and molecular biology. As a result, this will enable improved diagnostic tests, more precise diagnoses, greater predictability of disease course, and improved patient safety by selecting not only the right drug for a patient but also the appropriate dosage to reduce adverse effects.
ExL’s 2nd Stratified Medicine Conference will bring together the industry’s leading stratified and personalized medicine experts to provide you with unique take-home examples, case studies and multiple innovative strategies to implement stratified medicine initiatives within your own organizations.
By attending this conference, you will hear industry-specific case studies and examples including:
Pathways to partnership in therapeutic-diagnostic development
The future of translational research and stratified medicine Innovations in detecting molecular malfunctions impacting cancer research and
The role of biomarkers and translational science in the discovery organization
Pursuing stratified medicine: via predictive biomarkers to enhance clinical decision
The regulatory path to approval via stratified medicine Integrating clinical benefits with the economic implications
Examining the importance of pharmacokinetic biomarkers in early clinical
development decision points
Stratifying patients for clinical trials based on molecular and clinical data
Examining the challenges of companion diagnostics in pharmaceutical development
Exploring models for industry / academia collaboration in stratified medicine
Benefit from industry participation from Pfizer, Merck, MedImmune, Johnson & Johnson, Novartis, Selventa, EMD Serono, Daiichi Sankyo, MIT, and many more personalized and stratified medicine innovators and experts.